Champions Oncology (CSBR) Free Cash Flow (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Free Cash Flow of -$2.2 million for Q2 2026, down 132.39% year-over-year from $6.9 million in Q2 2025, and down 62.57% quarter-over-quarter from -$1.4 million in Q1 2026.
Champions Oncology (CSBR) Free Cash Flow (2010 - 2026) Analysis & Trends
Champions Oncology's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$2.2 million for Q2 2026.
- In Q2 2026, Free Cash Flow fell 132.39% year-over-year to -$2.2 million; the TTM figure through Apr 2026 stood at -$5.0 million (down 171.97% YoY), while the FY2026 annual figure was -$5.0 million, down 171.97% from the prior year.
- Free Cash Flow for Q2 2026 stood at -$2.2 million, down from -$1.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $6.9 million in Q2 2025, with the low at -$4.7 million in Q3 2023.
- The 5-year median for Free Cash Flow is -$110500.0 (2024), against an average of $12777.8.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow surged 480.97% in 2025, then plunged 982.05% in 2026.
- Champions Oncology's Free Cash Flow stood at $2.7 million in 2022, then sank by 80.98% to $510000.0 in 2023, then slumped by 173.92% to -$377000.0 in 2024, then sank by 360.74% to -$1.7 million in 2025, then declined by 28.79% to -$2.2 million in 2026.
- Business Quant data shows CSBR's Free Cash Flow at -$2.2 million in Q2 2026, -$1.4 million in Q1 2026, and -$1.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.24 Mn |
| Apr 30, 2026 | -2.24 Mn |
| Jan 31, 2026 | -1.38 Mn |
| Jan 31, 2026 | -1.38 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Oct 31, 2025 | -1.74 Mn |
| Jul 31, 2025 | 314,000.00 |
| Jul 31, 2025 | 314,000.00 |
| Apr 30, 2025 | 6.91 Mn |
| Apr 30, 2025 | 6.91 Mn |
| Jan 31, 2025 | 156,000.00 |
| Jan 31, 2025 | 156,000.00 |
| Oct 31, 2024 | -377,000.00 |
| Oct 31, 2024 | -377,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Jul 31, 2024 | 311,000.00 |
| Apr 30, 2024 | -1.81 Mn |
| Apr 30, 2024 | -1.81 Mn |
| Jan 31, 2024 | -1.01 Mn |
| Jan 31, 2024 | -1.01 Mn |